WHO preferred product characteristics for bivalent Salmonella Typhi/Paratyphi A vaccine for comprehensive protection against enteric fever– key considerations and research gaps
Gates Open Research · 2025
DOI: 10.12688/gatesopenres.16364.1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Gates Open Research, 2025. Verfasst von Ana Belen Ibarz Pavon und 13 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organization. Department of Immunization, Vaccines and Biologicals, Geneva, Switzerland. Hauptthemen laut MEDLINE: Typhoid Fever, Typhoid-Paratyphoid Vaccines, Paratyphoid Fever, Salmonella paratyphi A. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Gates Foundation.
Abstract (Originalsprache)
In 2021, Salmonella Paratyphi A caused >2 million illnesses, resulting in >14,000 deaths, most of which occurred among children under 5 years of age in socioeconomically deprived populations. Both typhoid fever and paratyphoid fever occur in such areas, but paratyphoid fever is currently concentrated in South Asia. Typhoid conjugate vaccines are recommended for the control of enteric fever in typhoid-endemic settings; however, there are increasing demands for the development of vaccines that can address enteric fever more broadly by including protection against paratyphoid fever. The WHO preferred product characteristics (PPC) and a research and development (R&D) technology roadmap are normative documents developed with the guidance and contribution of a multidisciplinary expert group following a standard methodological framework. In this paper, we summarize the PPC and R&D roadmap presenting the key attributes for a bivalent Salmonella enterica serovar Typhi and Paratyphi A vaccine, and discuss the identified key research and data gaps needed to optimize vaccine value and to inform public health and policy decisions, with a particular focus in paratyphoid and enteric fever endemic countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- World Health Organization. Department of Immunization, Vaccines and Biologicals, Geneva, Switzerland.
- International Vaccine Institute, Seoul, South Korea.
- UCLA Fielding School of Public Health, Los Angeles, USA.
- Korea University School of Medicine, Seoul, South Korea.
- Universidad Autonoma de Mexico. Facultad de Medicina, Mexico City, Mexico.
- University of Otago. Centre for International Health., Dunedin, New Zealand.
Förderung
- World Health Organization
- Gates Foundation
Zitieren
APA
Ibarz Pavon, A. B., Clemens, J., Craviotto, A., Crump, J. A., Garrett, D. O., Gordon, M. A., John, J., Keddy, K. H., Laurens, M. B., Liu, X., Marks, F., Pollard, A. J., Saha, S., & Wilder-Smith, A. (2025). WHO preferred product characteristics for bivalent Salmonella Typhi/Paratyphi A vaccine for comprehensive protection against enteric fever– key considerations and research gaps. Gates Open Research. https://doi.org/10.12688/gatesopenres.16364.1
Vancouver
Ibarz Pavon AB, Clemens J, Craviotto A, Crump JA, Garrett DO, Gordon MA, et al. WHO preferred product characteristics for bivalent Salmonella Typhi/Paratyphi A vaccine for comprehensive protection against enteric fever– key considerations and research gaps. Gates Open Research. 2025. doi:10.12688/gatesopenres.16364.1
BibTeX
@article{IbarzPavon2025,
author = {Ibarz Pavon, Ana Belen and Clemens, John and Craviotto, Alejandro and Crump, John A and Garrett, Denise O and Gordon, Melita A and John, Jacob and Keddy, Karen H and Laurens, Matthew B and Liu, Xinxue and Marks, Florian and Pollard, Andrew J and Saha, Senjuti and Wilder-Smith, Annelies},
title = {WHO preferred product characteristics for bivalent Salmonella Typhi/Paratyphi A vaccine for comprehensive protection against enteric fever– key considerations and research gaps},
journal = {Gates Open Research},
year = {2025},
doi = {10.12688/gatesopenres.16364.1}
}
EUVIMED